---
category: news
title: "Zacks Investment Research Downgrades Kiromic BioPharma (NASDAQ:KRBP) to Sell"
excerpt: "Kiromic BioPharma (NASDAQ:KRBP – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks,"
publishedDateTime: 2022-05-25T06:56:00Z
originalUrl: "https://www.defenseworld.net/2022/05/25/zacks-investment-research-downgrades-kiromic-biopharma-nasdaqkrbp-to-sell.html"
webUrl: "https://www.defenseworld.net/2022/05/25/zacks-investment-research-downgrades-kiromic-biopharma-nasdaqkrbp-to-sell.html"
type: article
quality: 1
heat: 1
published: false

provider:
  name: Defense World
  domain: defenseworld.net

topics:
  - AI in Healthcare
  - AI

secured: "CNKRqf4QdRA9O+fbGwcrPBeOPEleM+/dKteY2kEfnOVkMi4ZzM8khbBvmbeGfWUXXtL/EptVwgvCjmCWN/TuBYzntQNotDO3d0aRW2XB95lEAFT/aDVSXSm99VUMolMS4PsTJa1qIxs85EYdp6Ty402/GmmYGgPhNKZhDH9Oei8xIFvyh6PtMJMI2wUKKjvMNyuOLmnBzclzMJ4LIh+PHvHOyUiRIBC+6uDam2quhzaLtRxt+oFmxaAArY29mcafBvYeqhcB65KACrbJju6VBEjnxcfJkye7oEvWSjFq/3OkhqcpxW7+06HlGMcfUVSMJMkvC2xusOdWKasQh5S0RxJ7Z1X3NkIcIdNdldj0xuk=;PDJLqymUo+0ry/VaF4NJoQ=="
---

